Azenta, Inc. (AZTA)

Quarterly Report Filed: 2026-05-08

Key Insights

The filing shows a Q2 2026 period ending March 31, 2026, with multiple restatement adjustments and prior period error corrections indicated in the XBRL data, suggesting accounting adjustments that require investor attention.
The company is actively managing discontinued operations related to the B Medical Systems Business (held for sale as of December 23, 2025), which will impact comparative financial metrics and segment reporting going forward.
The presence of Edwards Vacuum LLC warranty claim adjustments and UK Biocentre transaction elements (dated March 4, 2026) indicate ongoing legal/operational matters that could affect financial results and require monitoring for resolution.

Current Report Filed: 2026-05-05

Key Insights

Azenta announced Q1 FY2026 financial results on May 5, 2026, but the actual earnings details are contained in the attached press release (Exhibit 99.1) which is not fully disclosed in this 8-K filing.
The company explicitly noted that Item 2.02 and the press release are not deemed 'filed' for Section 18 purposes and are not automatically incorporated by reference in future SEC filings, limiting the liability exposure for forward-looking statements.
The filing includes standard forward-looking statements disclaimer, indicating the company is managing guidance and expectations carefully while acknowledging material risks that could impact actual results versus projections.

Insider Trading Filed: 2026-04-30

Key Insights

William E. Martin III, President of Multiomics division, acquired 17,790 restricted stock units at $24.24 per share on 04/28/2026, representing a meaningful equity grant valued at approximately $431,000.
The RSUs vest over three years in equal 33% tranches (April 2027, 2028, and 2029), indicating a long-term retention incentive structure aligned with multi-year performance objectives.
This is an equity grant rather than open market purchase, suggesting the company is using stock-based compensation to retain executive talent in the Multiomics business unit.
The filing shows no existing beneficial ownership balance disclosed, indicating this may be a new position or first-time equity grant for this officer.

Insider Trading Filed: 2026-02-06

Key Insights

Robyn C. Davis, a director of Azenta, Inc., was granted 5,663 restricted stock units on February 5, 2026. The units are fully vested upon grant but the settlement is deferred until the later of her attainment of age 65 or her separation from service.
The restricted stock units were granted under the company's 2020 Equity Incentive Plan, indicating continued alignment between the director and the company's long-term performance.
Insider ownership and vesting patterns can provide insight into management's confidence in the company's future prospects and their commitment to shareholders.

Insider Trading Filed: 2026-02-06

Key Insights

Erica McLaughlin, a director of Azenta, Inc. (AZTA), acquired 5,663 shares of the company's common stock on February 5, 2026 at a price of $27.85 per share.
This transaction increases McLaughlin's direct beneficial ownership in Azenta to 22,521 shares, signaling her confidence in the company's prospects.
Insider buying, especially by a director, can be seen as a positive indicator for the company's future performance and is often viewed favorably by investors.

Insider Trading Filed: 2026-02-06

Key Insights

Frank Casal, a director of Azenta, Inc. (AZTA), acquired 7,243 shares of the company's common stock at $27.85 per share, increasing his direct beneficial ownership to 21,803 shares.
This insider purchase transaction suggests that Casal is positive about the company's prospects and potentially sees upside in the stock price.
Insider buying can be a positive signal for investors, as it may indicate the director's confidence in the company's future performance.

Insider Trading Filed: 2026-02-06

Key Insights

Dipal Doshi, a director of Azenta, Inc., has acquired 5,663 shares of the company's common stock through a stock grant, increasing his direct beneficial ownership to 9,703 shares.
The transaction was made under the company's 2020 Equity Incentive Plan, suggesting it was part of Doshi's compensation as a director.
Insider transactions, such as this stock grant, can provide insights into management's confidence in the company's outlook and future performance.

Insider Trading Filed: 2026-02-06

Key Insights

Insider Martin Madaus has been granted 5,663 restricted stock units (RSUs) that fully vest upon grant. This suggests he is being incentivized to remain with the company long-term.
The RSUs will not be settled until Madaus reaches age 65 or separates from the company, indicating he is not cashing out his equity award immediately.
Madaus' ownership of 9,703 shares after this grant suggests he has a substantial equity stake, aligning his interests with shareholders.

Insider Trading Filed: 2026-02-06

Key Insights

William L. Cornog, a director at Azenta Inc., received 5,663 restricted stock units on February 5, 2026, which will be settled in the company's common stock at a later date.
The restricted stock units granted to Cornog are fully vested upon grant, indicating his ongoing commitment to the company.
As a director, Cornog's equity award aligns his interests with those of Azenta's shareholders and may signal his confidence in the company's future.

Insider Trading Filed: 2026-02-06

Key Insights

Tina S. Nova, a director of Azenta, Inc., acquired 5,663 shares of the company's common stock on February 5, 2026 at a price of $27.85 per share.
This insider purchase suggests that Nova has a positive outlook on Azenta's future prospects and is willing to increase her stake in the company.
The transaction represents a notable increase in Nova's direct beneficial ownership of Azenta shares, which now stands at 15,772 shares.

Quarterly Report Filed: 2026-02-05

Key Insights

Azenta, Inc. (AZTA) reported solid financial performance in Q1 2026, with revenue of $4,053 million and EPS of $0.01, both in line with expectations.
The company's Core Products and Services segments continued to deliver stable results, indicating strong demand for their automated storage, cryogenic systems, and sample management offerings.
Azenta has incurred transformation costs related to strategic initiatives aimed at streamlining operations and improving long-term productivity, which may impact near-term profitability but could yield benefits in the future.

Current Report Filed: 2026-02-04

Key Insights

Azenta, Inc. reported its financial results for the fiscal quarter ended December 31, 2025, indicating the company's business performance during that period.
The filing includes a cautionary note regarding forward-looking statements, which suggests the results may contain projections or expectations about the company's future performance.
The press release attached to the filing is the primary source of information about Azenta's quarterly financial results, and investors should refer to it for details on the company's performance.

Current Report Filed: 2026-01-29

Key Insights

The company held its annual shareholder meeting on January 28, 2026, where key agenda items were approved, including the election of directors, an advisory vote on executive compensation, and an amendment to the 2020 Equity Incentive Plan.
Shareholders voted to ratify the appointment of PricewaterhouseCoopers LLP as the company's independent registered accounting firm for the 2026 fiscal year.
The company's stock symbol is AZTA, and it trades on the Nasdaq Stock Market.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information